Multi-Cancer Early Detection (MCED) Panel

About Mainz Biomed

Mainz Biomed is a commercial-stage biotech company dedicated to revolutionizing cancer screening through advanced molecular diagnostics. Its core product, ColoAlert®, is a CE-marked and FDA-registered stool DNA test for the detection of colorectal cancer and advanced adenomas. The company is actively pursuing a pivotal FDA clinical study (ReconAAsense) to gain U.S. market approval and is developing a portfolio of next-generation tests, including PancAlert for pancreatic cancer and a multi-cancer early detection (MCED) panel. Its strategy leverages a proprietary PCR-based platform to deliver accurate, accessible, and non-invasive screening solutions.

Therapeutic Areas